State-owned Hebei antibiotics pioneer, one of China's oldest large-scale penicillin and API manufacturers.
State-owned Hebei antibiotics pioneer, one of China's oldest large-scale penicillin and API manufacturers.
Sells antibiotic active ingredients such as penicillin by the tonne to generic drugmakers worldwide, and finished drugs to hospitals, so earnings follow the global price of a commodity-like ingredient and the cost of grain-based fermentation inputs. A Hebei state-owned group controls it.
In one line: A Chinese state-owned Pfizer-generics ancestor.
Moat: none (scale). Legacy state-owned scale in commodity antibiotics, but limited pricing power against newer low-cost rivals.
Headquarters: Shijiazhuang, Hebei, China · Founded: 1953 · Employees: 9,972
Size North China Pharmaceutical (600812.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.08B, the 2003rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.46 on 18 Nov 2026.
Performance Over six months the shares fell 11.7%, against -7.1% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 20 in its peer set.
Growth Revenue fell 20.7% over the last twelve months (peer median -1.2%); the operating margin is 5.4% (peer median 8.9%).
Valuation It trades at 2.4× enterprise value to sales against a peer median of 3.0× (8th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is -4%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.2 points below its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥7.77B | CN¥9.20B | CN¥9.83B | CN¥10.1B | CN¥10.5B |
| Revenue growth | — | -6% | -2% | -4% | — |
| Gross profit | CN¥2.77B | CN¥2.55B | CN¥2.91B | CN¥3.05B | CN¥3.33B |
| EBITDA | n/a | CN¥1.58B | CN¥1.55B | CN¥1.43B | CN¥691M |
| Net income | CN¥89.4M | CN¥183M | CN¥127M | CN¥4.89M | -CN¥689M |
| Free cash flow | CN¥697M | CN¥695M | CN¥446M | CN¥402M | CN¥456M |
| Capital expenditure | CN¥539M | CN¥542M | CN¥784M | CN¥623M | CN¥550M |
| Total debt | CN¥11.6B | CN¥11.7B | CN¥11.9B | CN¥11.7B | CN¥11.9B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| North China Pharmaceutical 600812.SS | $1.08B | -12% | -21% | 5% | 2.4× | 1.0% |
| Shandong Lukang Pharmaceutical 600789.SS | $1.05B | -18% | -7% | 3% | 1.5× | 2.5% |
| Northeast Pharmaceutical 000597.SZ | $895M | -14% | -6% | 3% | 0.9× | -7.6% |
| Harbin Pharmaceutical 600664.SS | $1.78B | +32% | +2% | 5% | 0.7× | -5.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600812.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -19.1% | -1.1% | 3rd lowest of 21 |
| 6-month return | -11.7% | -7.1% | 7th lowest of 20 |
| Distance from 52-week high | -35.4% | -26.8% | 7th lowest of 21 |
| Revenue growth (TTM) | -20.7% | -1.2% | 3rd lowest of 17 |
| Operating margin | 5.4% | 8.9% | 8th lowest of 18 |
| EV / Sales | 2.4× | 3.0× | 8th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 1.0% | 3.4% | 5th least demanding of 12 |
| Growth delivered (Del g) | -4.2% | +11.3% | 2nd lowest of 12 |
| Hurdle (Req g minus delivered) | +5.2 pp | -4.0 pp | 3rd most demanding of 12 |
| ROIC minus cost of capital | -0.2 pp | -1.5 pp | 9th highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| North China Pharmaceutical 600812.SS | China | $1.08B | -12% | -21% | 5% | 2.4× | 1.0% | -4.2% |
| Omeros OMER | United States | $1.08B | +24% | n/a | -56% | 17.3× | n/a | n/a |
| MedinCell MEDCL.PA | France | $1.09B | +4% | -23% | -131% | 49.6× | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.09B | +29% | n/a | n/a | n/a | n/a | n/a |
| Vetoquinol VETO.PA | France | $1.10B | +19% | -1% | 15% | 1.5× | -3.6% | +4.2% |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.11B | -7% | -9% | 11% | 2.3× | 4.9% | +11.3% |
| ST Pharm 237690.KS | South Korea | $1.11B | -51% | +26% | 18% | 3.5× | 4.2% | +21.7% |
| Viyash Scientific VIYASH.NS | India | $1.11B | +3% | +124% | 13% | 2.9× | 36.3% | +20.4% |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.12B | n/a | n/a | n/a | n/a | n/a | n/a |
| Everest Medicines 1952.HK | Hong Kong | $1.05B | -20% | +193% | -5% | 3.0× | n/a | n/a |
| GC Biopharma 006280.KS | South Korea | $1.12B | -10% | -3% | 4% | 1.2× | n/a | n/a |
| Blue Jet Healthcare BLUEJET.NS | India | $1.05B | +19% | -7% | 28% | 8.1× | 40.8% | +13.8% |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.05B | -18% | -7% | 3% | 1.5× | 2.5% | +6.5% |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.04B | +33% | +5% | 24% | 3.2× | -5.6% | +12.7% |
| Savara SVRA | United States | $1.04B | -7% | n/a | n/a | n/a | n/a | n/a |
| Cosmo CMHC.SW | Switzerland | $1.13B | -30% | -45% | -13% | 8.2× | n/a | n/a |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -11% | +31% | -7% | 1.7× | -6.5% | -7.7% |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.14B | -12% | -2% | 15% | 4.2× | 3.4% | -1.2% |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -10% | +7% | 9% | 1.2× | -0.3% | +12.1% |
| Kissei Pharmaceutical 4547.T | Japan | $1.14B | +3% | +6% | 6% | 1.4× | n/a | n/a |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.03B | -33% | -2% | 13% | 4.2× | 4.4% | +7.7% |